The New England journal of medicine, 2023-12, Vol.389 (24), p.2233-2244
- Wilson, Eleanor
- Goswami, Jaya
- Baqui, Abdullah H.
- Doreski, Pablo A.
- Perez-Marc, Gonzalo
- Zaman, Khalequ
- Monroy, Jorge
- Duncan, Christopher J.A.
- Ujiie, Mugen
- Rämet, Mika
- Pérez-Breva, Lina
- Falsey, Ann R.
- Walsh, Edward E.
- Dhar, Rakesh
- Wilson, Lauren
- Du, Jiejun
- Ghaswalla, Parinaz
- Kapoor, Archana
- Lan, Lan
- Mehta, Shraddha
- Mithani, Runa
- Panozzo, Catherine A.
- Simorellis, Alana K.
- Kuter, Barbara J.
- Schödel, Florian
- Huang, Wenmei
- Reuter, Caroline
- Slobod, Karen
- Stoszek, Sonia K.
- Shaw, Christine A.
- Miller, Jacqueline M.
- Das, Rituparna
- Chen, Grace L.
2023
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Wilson, Eleanor
- Goswami, Jaya
- Baqui, Abdullah H.
- Doreski, Pablo A.
- Perez-Marc, Gonzalo
- Zaman, Khalequ
- Monroy, Jorge
- Duncan, Christopher J.A.
- Ujiie, Mugen
- Rämet, Mika
- Pérez-Breva, Lina
- Falsey, Ann R.
- Walsh, Edward E.
- Dhar, Rakesh
- Wilson, Lauren
- Du, Jiejun
- Ghaswalla, Parinaz
- Kapoor, Archana
- Lan, Lan
- Mehta, Shraddha
- Mithani, Runa
- Panozzo, Catherine A.
- Simorellis, Alana K.
- Kuter, Barbara J.
- Schödel, Florian
- Huang, Wenmei
- Reuter, Caroline
- Slobod, Karen
- Stoszek, Sonia K.
- Shaw, Christine A.
- Miller, Jacqueline M.
- Das, Rituparna
- Chen, Grace L.
- Titel
- Efficacy and Safety of an mRNA-Based RSV PreF Vaccine in Older Adults
- Ist Teil von
- The New England journal of medicine, 2023-12, Vol.389 (24), p.2233-2244
- Ort / Verlag
- United States: Massachusetts Medical Society
- Erscheinungsjahr
- 2023
- Quelle
- Free E-Journal (出版社公開部分のみ）
- Beschreibungen/Notizen
- In a placebo-controlled, phase 2–3 trial, one dose of mRNA-1345 led to a lower incidence of RSV disease among adults 60 years of age or older. Solicited local and systemic adverse reactions occurred more often with the vaccine.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0028-4793eISSN: 1533-4406DOI: 10.1056/NEJMoa2307079Titel-ID: cdi_proquest_miscellaneous_2902954672
- Format
- –
- Schlagworte
- Aged, Aging, Aging General, Antibodies, Viral, Chronic obstructive pulmonary disease, Clinical Medicine, Clinical Medicine General, Clinical trials, Confidence intervals, Critical Care, Critical Care General, Double-Blind Method, Geriatrics, Glycoproteins, Humans, Infections, Infectious Disease, Infectious Disease General, Middle Aged, Morbidity, mRNA, mRNA Vaccines - adverse effects, mRNA Vaccines - therapeutic use, Older people, Outpatient-Based Clinical Medicine, Placebos, Product development, Pulmonary, Respiratory diseases, Respiratory syncytial virus, Respiratory Syncytial Virus Infections - epidemiology, Respiratory Syncytial Virus Infections - prevention & control, Respiratory Syncytial Virus Vaccines - adverse effects, Respiratory Syncytial Virus Vaccines - therapeutic use, Respiratory Syncytial Virus, Human - genetics, Respiratory tract diseases, Respiratory Tract Diseases - diagnosis, Respiratory Tract Diseases - epidemiology, Respiratory Tract Diseases - prevention & control, Safety, Side effects, Statistical analysis, Success, Treatment Outcome, Vaccine efficacy, Vaccines, Viral Infections